Lisa Situ
@lisasitu.bsky.social
330 followers 710 following 26 posts
Assistant Editor at Cancer Discovery, published by AACR. BBS Harvard PhD '24 and proud UCLA Bruin. Views are my own. Link to sign up for Cancer Discovery News alerts: https://aacrjournals.org/pages/alerts
Posts Media Videos Starter Packs
lisasitu.bsky.social
Out today: Molecular Residual Disease Precedes Disease-Free Survival Events by Months, a #ResearchWatch summary of an impactful exploratory post hoc analysis of the ADAURA trial by Dr. Roy Herbst, Dr. Thomas John, Dr. Yi-Long Wu, and colleagues

aacrjournals.org/cdnews/news/...
Molecular Residual Disease Precedes Disease-Free Survival Events by Months
Major Finding: Molecular residual disease (MRD) preceded death or clinical recurrence in the ADAURA trial by nearly 5 months. Concept: Longitudinal MRD monitoring may stratify risk for patients with E...
aacrjournals.org
lisasitu.bsky.social
Very interesting findings, congratulations once more on the study! 🎉
lisasitu.bsky.social
ICYMI: "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours" - a #ResearchWatch summary of a study by Ignacio Melero, Eugen Leo, and colleagues #ClinicaNavarra #CIMA_unav #visugromab #CatalYm

doi.org/10.1158/2159...
GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition
Main Findings: Visugromab, a GDF-15 blocking antibody, is tolerable and elicits clinical responses in combination with nivolumab.Concept: GDF-15 may represent a mechanism of anti-PD-1 resistance that ...
doi.org
Reposted by Lisa Situ
lisasitu.bsky.social
Congratulations on these exciting results, Nick and team! We were very happy to feature the work! #ResearchWatch
lisasitu.bsky.social
I love this!! Heading to my first workshop now 🤗 but I’m definitely on the hunt to find this mascot!
lisasitu.bsky.social
San Diego morning fog forced a flight diversion to Vegas… but finally made it! Very excited to be here at #ASH24!
lisasitu.bsky.social
Congratulations on the publication of this important work! @ejvillablanca.bsky.social @martinaparigi.bsky.social
lisasitu.bsky.social
How do barrier tissues promote repair and regeneration without tipping the ⚖️ toward malignant transformation?

Find out in today's #ResearchWatch summary of a recent 📜 by Srustidhar Das, S. Martina Parigi, Xinxin Luo, Eduardo J. Villablanca, and colleagues.

aacrjournals.org/cdnews/news/...
The Liver X Receptor Axis Balances Intestinal Regeneration and Tumorigenesis
Major Finding: The liver X receptor (LXR) pathway drives intestinal regeneration and limits tumorigenesis.Concept: Transcriptomic and pharmacologic studies define a CYP27A1–LXR–TLS signaling axis in i...
aacrjournals.org
lisasitu.bsky.social
That is awesome! I'm excited to learn about germline variants in pediatric AML from @laurenmharmon.bsky.social -- hope to see you at your poster Monday night! Safe travels to you and the whole team 🤗
lisasitu.bsky.social
Countdown to #ASH24! Are you heading to San Diego this weekend? If so, I'd love to connect! If you're presenting, please let me know - I want to hear about your work!
lisasitu.bsky.social
Last week in Cancer Discovery News: GD2-CAR T-cell Therapy is Safe in H3K27M+ Diffuse Midline Glioma, a #ResearchWatch summary of promising clinical findings by Michelle Monje, Sneha Ramakrishna, Crystal Mackall, and colleagues.

doi.org/10.1158/2159...
GD2-CAR T-cell Therapy is Safe in H3K27M+ Diffuse Midline Glioma
Main Finding: A phase I clinical trial demonstrates the safety of GD2-targeted CAR T-cell therapy in H3K27M+ diffuse midline glioma.Concept: H3K27M+ diffuse midline gliomas express high levels of GD2,...
doi.org